Prescribed and Non-prescribed Gabapentin Use Among Persons Seeking Inpatient Opioid Detoxification
Overview
Affiliations
Background: Persons with opioid use disorder (OUD) are at increased risk for gabapentin misuse. Rising rates of concomitant gabapentin-opioid use in the U.S. are concerning given heightened risk of fatal overdose.
Objective: To examine predictors of ever using gabapentin among persons seeking treatment for opioid use and to assess if reasons for gabapentin use differed by gender and how gabapentin was procured (prescribed, non-prescribed, or both).
Method: Persons with OUD were recruited from a managed withdrawal program. t-Tests and Pearson χ2 tests of independence were used to compare reasons for gabapentin use by gender and source of acquisition.
Results: Among participants (n = 401; 69.1% male, 84.5% White, 86.8% sought treatment for heroin use, 90.0% insured), female gender, higher educational attainment, injection drug use (IDU), history of overdose, and chronic pain were associated with gabapentin use. Overall, reasons for use were similar across genders among those reporting a history of gabapentin use (65.8%), although males were more likely to use to get high than females. About half (47.0%) reported only using gabapentin that was not prescribed, 20.5% had only used prescribed gabapentin, and 32.5% reported prescribed and non-prescribed use. Persons prescribed gabapentin were most likely to use it to control pain (81.5%); for those using diverted gabapentin only and those reporting both prescribed and non-prescribed gabapentin use, the most common reasons for intake were to: get high, increase effects of heroin, substitute for opioids, and help with opioid withdrawal.
Conclusions: In this sample of people with OUD entering inpatient detoxification program, a majority reported a history of gabapentin use, with most using diverted gabapentin. The range of reasons for gabapentin use point to the need to better understand why co-use is common.
Ciesluk B, Inglis D, Parke A, Troup L PLoS One. 2024; 19(10):e0310655.
PMID: 39383139 PMC: 11463789. DOI: 10.1371/journal.pone.0310655.
Hiranita T, Flynn S, Grisham A, Mijares A, Murphy E, France C J Pharmacol Exp Ther. 2024; 391(2):317-334.
PMID: 39179416 PMC: 11493450. DOI: 10.1124/jpet.124.002323.
Lee-Easton M, Magura S, Abu-Obaid R, Reed P, Allgaier B, Fish E J Psychoactive Drugs. 2024; :1-12.
PMID: 38329134 PMC: 11306407. DOI: 10.1080/02791072.2024.2314220.
Effects of Gabapentinoids on Heroin-Induced Ventilatory Depression and Reversal by Naloxone.
Flynn S, France C ACS Pharmacol Transl Sci. 2023; 6(4):519-525.
PMID: 37082751 PMC: 10111619. DOI: 10.1021/acsptsci.2c00230.
Overdose deaths involving non-BZD hypnotic/sedatives in the USA: Trends analyses.
Tardelli V, Bianco M, Prakash R, Segura L, Castaldelli-Maia J, Fidalgo T Lancet Reg Health Am. 2023; 10:100190.
PMID: 36777690 PMC: 9904096. DOI: 10.1016/j.lana.2022.100190.